Basic Information
RNALocate ID: | RLID:11002792 |
RNA Symbol: | hsa-miR-200a-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-200a-5p |
RNA ID: | miRBase:MIMAT0001620 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 31746410 |
Tissue/Cell Line: | Peripheral blood |
Method: | qRT-PCR |
Condition: | Upregulated |
Description: | To validate the sequencing data for certain miRNAs, the expression levels of six upregulated miRNAs (hsa-miR-148a-5p, hsa-miR-200a-5p, hsa-miR-210a-3p, hsa-miR-378a-3p, hsa-miR-483-5p and hsa-miR-7110-5p) and two downregulated microRNAs (hsa-miR-92b-3p and hsa-miR-150-5p) in the exosome of TNBC patients (n=20) and healthy controls (n=20) were verified by RT-qPCR. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11002793 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11002794 | Exosome | Breast milk | 22211110 |
RLID:11002795 | Exosome | Brain tissue | 23382797 |
RLID:11002796 | Exosome | Plasma | 23663360 |
RLID:11002797 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000140 | Exosome | Colon tissue|Tongue tissue | |
RLID-D:11000456 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-200a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-25945 |
MNDR | hsa-miR-200a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-25946 |
MNDR | hsa-miR-200a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-25947 |
MNDR | hsa-miR-200a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25948 |
MNDR | hsa-miR-200a-5p | Lymphoma | MNDR-E-MI-25949 |
MNDR | hsa-miR-200a-5p | Prostate cancer | MNDR-E-MI-25950 |
MNDR | hsa-miR-200a-5p | Gastric cancer | MNDR-E-MI-25951 |
MNDR | hsa-miR-200a-5p | Bladder cancer | MNDR-E-MI-25952 |
MNDR | hsa-miR-200a-5p | Parkinson disease | MNDR-E-MI-25953 |
MNDR | hsa-miR-200a-5p | Breast cancer | MNDR-E-MI-25954 |
MNDR | hsa-miR-200a-5p | Thyroid cancer | MNDR-E-MI-25955 |
MNDR | hsa-miR-200a-5p | Pituitary neoplasms | MNDR-E-MI-25956 |
MNDR | hsa-miR-200a-5p | Pancreatic cancer | MNDR-E-MI-25957 |
MNDR | hsa-miR-200a-5p | Rectum adenocarcinoma | MNDR-E-MI-25958 |
MNDR | hsa-miR-200a-5p | Nephroblastoma | MNDR-E-MI-25959 |
MNDR | hsa-miR-200a-5p | Colon cancer | MNDR-E-MI-25960 |
MNDR | hsa-miR-200a-5p | Colon adenocarcinoma | MNDR-E-MI-25961 |
MNDR | hsa-miR-200a-5p | Familial ovarian cancer | MNDR-E-MI-25962 |
MNDR | hsa-miR-200a-5p | Carcinoma ductal breast | MNDR-E-MI-25963 |
MNDR | hsa-miR-200a-5p | Invasive ductal carcinoma | MNDR-E-MI-25964 |
MNDR | hsa-miR-200a-5p | Glioma | MNDR-E-MI-25965 |
MNDR | hsa-miR-200a-5p | Breast carcinoma | MNDR-E-MI-25966 |
MNDR | hsa-miR-200a-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-25967 |
MNDR | hsa-miR-200a-5p | Cervical adenocarcinoma | MNDR-E-MI-25968 |
MNDR | hsa-miR-200a-5p | Gastric adenocarcinoma | MNDR-E-MI-25969 |
MNDR | hsa-miR-200a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-25970 |
MNDR | hsa-miR-200a-5p | Pituitary adenoma | MNDR-E-MI-25971 |
MNDR | hsa-miR-200a-5p | Lung squamous cell carcinoma | MNDR-E-MI-25972 |
MNDR | hsa-miR-200a-5p | Lung adenocarcinoma | MNDR-E-MI-25973 |
MNDR | hsa-miR-200a-5p | Ovarian carcinoma | MNDR-E-MI-25974 |
MNDR | hsa-miR-200a-5p | Bladder urothelial carcinoma | MNDR-E-MI-25975 |
MNDR | hsa-miR-200a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-25976 |
MNDR | hsa-miR-200a-5p | Carcinoma renal cell | MNDR-E-MI-25977 |
MNDR | hsa-miR-200a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25978 |
MNDR | hsa-miR-200a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-25979 |
MNDR | hsa-miR-200a-5p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-25980 |
MNDR | hsa-miR-200a-5p | Cholangiocarcinoma | MNDR-E-MI-25981 |
MNDR | hsa-miR-200a-5p | Lung small cell carcinoma | MNDR-E-MI-25982 |
MNDR | hsa-miR-200a-5p | Synovial sarcoma | MNDR-E-MI-25983 |
MNDR | hsa-miR-200a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-25984 |
MNDR | hsa-miR-200a-5p | Testicular germ cell cancer | MNDR-E-MI-25985 |
MNDR | hsa-miR-200a-5p | Breast invasive carcinoma | MNDR-E-MI-25986 |
MNDR | hsa-miR-200a-5p | Hepatocellular carcinoma | MNDR-E-MI-25987 |
MNDR | hsa-miR-200a-5p | Familiar ovarian carcinoma | MNDR-E-MI-25988 |
MNDR | hsa-miR-200a-5p | Barrett's adenocarcinoma | MNDR-E-MI-25989 |
MNDR | hsa-miR-200a-5p | Tonsil cancer | MNDR-E-MI-25990 |
MNDR | hsa-miR-200a-5p | Skin cutaneous melanoma | MNDR-E-MI-25991 |
MNDR | hsa-miR-200a-5p | Skin melanoma | MNDR-E-MI-25992 |
MNDR | hsa-miR-200a-5p | Colorectal cancer | MNDR-E-MI-25993 |
MNDR | hsa-miR-200a-5p | Barrett's carcinogenesis | MNDR-E-MI-25994 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CTNNB1 | Homo sapiens | RR00378128 |
TOP